Direct thrombin inhibitors

Seminars in Hematology

Volumn 39, Issue 3, 2002, Pages 187-196

  Kaplan, Karen L ^a   Francis, Charles W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; HEPARIN DERIVATIVE; HIRULOG; LEPIRUDIN; MELAGATRAN; SERINE PROTEINASE; THROMBIN; THROMBIN INHIBITOR; XIMELAGATRAN; ANTICOAGULANT AGENT;

BLEEDING; BLOOD CLOTTING; CATALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; THROMBOCYTOPENIA; THROMBOSIS; ANIMAL; CHEMISTRY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; CORONARY DISEASE; HUMANS; THROMBIN; TREATMENT OUTCOME;

EID: 0035992747     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/shem.2002.34092     Document Type: Article

References (81)

1. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases
2. Hirudin in acute myocardial infarction: Safety report from the thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial
3. Hirudin in acute myocardial infarction
4. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor
5. Inhibition of thrombin and trypsin by tripeptide aldehydes
6. Efficacy and safety of subcutaneous melagatran and oral ximelagatran (pINN, formerly H376/95) as prophylaxis against thromboembolic complications following general abdominal surgery
7. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant hirudin
8. Catabolism of hirudin and thrombin-hirudin complexes
9. Treatment with bivalirudin (Hirulog) as compared with heparin during angioplasty for unstable or postinfarction angina
10. DDAVP reduces bleeding during continued hirudin administration in the rabbit
11. Effect of direct thrombin inhibition with bivalirudin (Hirulog) on restenosis after coronary angioplasty
12. Argatroban, a selective, potent thrombin inhibitor
13. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP39393) on bleeding in the rat
14. Pharmacokinetics of rechirudin in healthy volunteers after intravenous administration
15. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism after total hip arthroplasty
16. How thrombin "talks" to cells. Molecular mechanisms and roles in vivo
17. Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets
18. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor
19. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
20. The pharmacokinetics and pharmacodynamics of ximelagatran in patients with mild-to-moderate impairment of liver function
21. Effect of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (p1NN, formerly H376/95), on activated partial thromboplastin time in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism
22. The pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H376/95), in orthopaedic surgery patients treated to prevent deep venous thrombosis and pulmonary embolism
23. The pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran in patients with severe renal impairment
24. The roles of protein C and thrombomodulin in the regulation of blood coagulation
25. Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C
26. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers
27. Bleeding effects of antithrombin drugs can be neutralized by activated FVIIa (NovoSeven) and combinations of other plasma-derived products
28. Randomized, double-blind comparative study of ximelagatran (pINN, formerly H 376/95), an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee arthroplasty
29. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
30. Hirudin elimination by hemofiltration: A comparative in vitro study of different membranes
31. Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery
32. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
33. Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
34. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin
35. Uber die einwirkung eines secretes des officinellen blutegels auf die gerinnbarkeit des blutes
36. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement
37. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment
38. Novastan (brand of argatroban): A small-molecule direct thrombin inhibitor
39. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro
40. Dosage adjustment of argatroban justified in combination with glycoprotein IIb/IIIa receptor antagonist: Laboratory and clinical implications
41. Heparin-induced thrombocytopenia
42. Thrombin inhibition in the acute phase of stroke using argatroban
43. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease
44. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4
45. D-Phe-Pro-Arg-CH2Cl-A selective affinity label for thrombin
46. Inhibitory effect of melagatran and hirudin on clot-bound thrombin
47. Argatroban use in patients with heparin-induced thrombocytopenia during percutaneous coronary intervention
48. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention (PCI) in patients with heparin-induced thrombocytopenia
49. Results of phase 2/3 trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT)
50. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
51. More profound inhibition of endothelial cell mediated APC generation by low molecular mass thrombin inhibitors than by other thrombin inhibitors
52. The binding of thrombin by fibrin
53. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172)
54. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes
55. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin
56. A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction
57. Argatroban use in patients with a history of heparin-induced thrombocytopenia who require acute anticoagulation
58. Argatroban
59. 131I]lepirudin in baboons
60. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction
61. Safety observations from the pilot phase of the randomized r-Hirudin for improvement of thrombolysis (HIT-III) study: A study of the Arbeitsgemeinschaft Leitender Kardolischer Krankenhausartze (ALKK)
62. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: A pilot study
63. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with myocardial infarction without ST elevation: A randomized trial
64. Kinetic mechanism for the interaction of Hirulog with thrombin
65. A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation
66. The use of bivalirudin in patients with renal impairment
67. Lack of effect of obesity on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran
68. THRIVE 1: Efficacy and tolerability of the novel, oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis
69. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
70. Identification of the regions of alpha-thrombin involved in its interactions with hirudin
71. Kinetics of the inhibition of thrombin by hirudin
72. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
73. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
74. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndrome
75. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty
76. Molecular interactions of thrombin
77. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers
78. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia
79. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
80. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO)
81. Plasma fibrinopeptide A levels in symptomatic venous thromboembolism